Abstract 104P
Background
Third-line treatment options are limited in metastatic colorectal cancer (mCRC). Fruquintinib, regorafenib and trifluridine–tipiracilare usually used as third-line treatmentsin chemotherapy-refractory mCRC.Recently, we found that the rechallenge-chemotherapy showed good efficacy in third-line therapy of mCRC. However, there is currently a lack of head-to-head comparison between the aforementioned drugs. Herein, the aim of this study is to review the efficacy of standard therapy versus rechallenge-chemotherapy in the real world.
Methods
We identified 107 eligible patients with mCRC who received third-line therapy in our hospital. All statistical analyses were performed using RStudio version 3.5.2. Time-to-event analysis was plotted on Kaplan-Meier curves, and hazard ratio was calculated using Cox regression. The spider and waterfall plots were used to compare the curative effect between the two groups according to RECIST 1.1. In all analyses, a P value of ＜ 0.05 was considered to indicate a significant difference.
Results
From April 17, 2018 to June 7, 2023,a total of 107 mCRC patients (68 males and 39 females) were retrospectively enrolled in the study, with a median follow-up time of 6.6 (range, 0.4–37.2) months.54 patients received standard therapy and 53 patients received chemotherapy rechallenge. The median overall survival (OS) was 6.6 months (95% CI, 5.3 to 10.9 months) in standard group and 16.6 months (95% CI, 11.5 to 32.6 months) in rechallenge group. The median progression-free survival (PFS) was 2.9 months(95% CI, 2.4 to 4.2 months) in standard group and 5.2months(95% CI, 4.3 to 6.9 months) in rechallenge group.The objective response rate（ORR）and disease control rate (DCR) was 9.4%(5/53) /66%(35/53) and 1.8%(1/54)/40.7%(22/54) in the chemotherapy rechallenge group and standard therapy group, respectively.
Conclusions
Among patients with refractory metastatic colorectal cancer in the third-line therapy, the rechallenge-chemotherapy resulted in longer overall survival than the standard therapy indicating a new treatment strategy.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.